Grades, scores, and FDA catalyst signals for Oncology stocks tracked by BiotechSign
Cancer drug development is the largest single segment of biotech, commanding the majority of FDA approvals and R&D spending each year. Oncology PDUFA dates drive some of the most volatile binary events in the market — approval can send a stock up 100–300% overnight, while a Complete Response Letter (CRL) can erase 60–80% of market cap in hours. The sector spans small-molecule chemotherapies, targeted therapies, immuno-oncology (checkpoint inhibitors, CAR-T), and antibody-drug conjugates (ADCs). Investors must assess tumor type, line of therapy, competitive landscape, and FDA precedent when evaluating PDUFA catalysts. Combination regimens and biomarker-driven patient selection have become dominant themes in modern oncology development.